2 years ago

Tenpoint Therapeutics Secures $70 Million in Series A Funding to Develop Vision-Restoring Therapies

  • Tenpoint Therapeutics, a Cambridge, UK-based biotechnology company, has raised $70 million in Series A funding

  • The company will use the funds to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions

  • Tenpoint was founded by scientists from Moorfields Eye Hospital, University College London Institute of Ophthalmology, Institut de la Vision in Paris, and the University of Washington, who have developed engineered cell-based therapeutics and performed translational research to establish proof-of-concept

  • Backers included British Patient Capital, F-Prime Capital, Sofinnova Partners, Qiming Venture Partners USA, Eight Roads, and the UCL Technology Fund.

      • ProblemHealthcare

      "People with degenerative ocular diseases losing their vision due to cell destruction caused by age-related and inherited conditions."

      Solution

      "Tenpoint Therapeutics is developing regenerative medicine platform to replace cells destroyed by both age-related and inherited ocular diseases, restoring vision for people with degenerative ocular diseases."

      Covered on